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Abstract
Purpose The treatment decisions of melanoma patients are poorly understood. Most research on cancer patient decision-making
focuses on limited components of specific treatment decisions. This study aimed to holistically characterize late-stage melanoma
patients’ approaches to treatment decision-making in order to advance understanding of patient influences and supports.
Methods (1) Exploratory analysis of longitudinal qualitative data to identify themes that characterize patient decision-making.
(2) Pattern analysis of decision-making themes using an innovative method for visualizing qualitative data: a hierarchically-
clustered heatmap. Participants were 13 advanced melanoma patients at a large academic medical center.
Results Exploratory analysis revealed eight themes. Heatmap analysis indicated two broad types of patient decision-makers.
BReliant outsiders^ relied on providers for medical information, demonstrated low involvement in decision-making, showed a
low or later-in-care interest in clinical trials, and expressed altruistic motives. BActive insiders^ accessed substantial medical
information and expertise in their networks, consulted with other doctors, showed early and substantial interest in trials, dem-
onstrated high involvement in decision-making, and employed multiple decision-making strategies.
Conclusion We identified and characterized two distinct approaches to decision-making among patients with late-stage melano-
ma. These differences spanned a wide range of factors (e.g., behaviors, resources, motivations). Enhanced understanding of
patients as decision-makers and the factors that shape their decision-making may help providers to better support patient
understanding, improve patient-provider communication, and support shared decision-making.
Keywords Decisionmaking . Ethnography . Ethnoarray approach .Melanoma
Introduction
Melanoma is currently the fifth most common cancer in the
USA and its incidence is steadily rising [1]. Approximately
2.2% of individuals in the USA will be diagnosed with the
disease during their lifetime [1]. Melanoma is more common
among men than among women (29.2% vs. 17.3% of new
cases), and among white and non-Hispanic men (34.4% and
33.1%) and women (20.9% and 19.9%) than among other
groups (≤ 5% of new cases) [1, 2]. Metastatic melanoma is
particularly deadly, with only 20% patients surviving at least
5 years post-diagnosis [1]. In recent years, however, the prog-
nosis of patients with advanced melanoma has improved with
the development of novel immunotherapies and targeted ther-
apies [3–5]. These complement longer-standing treatments
such as systemic chemotherapy, palliative surgery, or pallia-
tive radiation [3, 4].
Like all late-stage cancer patients, late-stage melanoma pa-
tients face difficult decisions in the course of their medical
care. These decisions may be difficult technically (e.g., under-
standing different therapies), emotionally (e.g., deciding when
to curtail curative treatment), and ethically (e.g., deciding
whether to join a clinical trial). In recent years, decision-
making has grown even more complex. Novel immunother-
apies and targeted agents have greatly expanded the number
of treatment and experimental options available for late-stage
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melanoma patients [6], each of which has its unique mix of
potential therapeutic benefits, side effects, and costs.
Relatively little is known about decision-making among
melanoma patients, particularly at later stages. Some studies
have examined patients’ preferences regarding treatment op-
tions, or their preferred or experienced level of involvement in
treatment decision-making [7–9]. These investigations have
focused on, for example, German melanoma patients’ pre-
ferred role in treatment decisions [8], and US melanoma pa-
tients’ preferences regarding adjuvant treatments [9]. We
found no studies of decision-making among melanoma pa-
tients with advanced disease, though some studies examine
related issues such as coping [10].
Far more is known about influences on and levels of in-
volvement in decision-making among cancer patients with
breast or prostate cancer, or earlier-stage cancer patients more
broadly [11–16]. However, even in this literature, most re-
search focuses on a single influence on, or a narrow aspect
of, cancer patients’ decision-making. These include the
amount of control or involvement the patient wants in
decision-making [8, 13, 17, 18], the patient-provider relation-
ship [19–21], assessments of quantity versus quality of life [7,
9], or decisional satisfaction or regret [22, 23].
While many studies examine one or more decision-making
domains, our review found few that sought to characterize this
complex process holistically—examining how decision-
making reflected the simultaneous interplay of a variety of fac-
tors such as patient-provider interactions, patients’ information-
seeking behaviors, logistics, and patient preferences [14, 15,
24–26]. Studies of cancer screening among diverse patient pop-
ulations illustrate that reductionist frameworks for analyzing
decision-making may limit our ability to detect the broader
holistic frameworks within which patients make specific treat-
ment decisions [27–29]. Given the expanding treatment options
for melanoma patients and calls for research that can support
patient-centered care and shared decision-making [11, 30–32],
a holistic research approach that captures the broad frameworks
that patients bring to the decision-making process may provide
novel insights.
This study aims to characterize late-stage melanoma pa-
tients holistically as treatment decision-makers. To do this,
we draw on prospectively-collected ethnographic data and
use two analytic approaches that support complex multifacto-
rial inquiries. These analyses are centered on the person, and
the broader relational and informational context in which they
make decisions, rather than on any single decision event or
process [30, 33].
Methods
This paper draws on the Cancer Patient Deliberation Study, a
multi-site ethnographic study of decision-making among late-
stage cancer patients. We overview the study’s methods here.
Additional details of the study design and procedures are
available elsewhere [34–37].
Data
We use data from late-stage melanoma patients who par-
ticipated in the Cancer Patient Deliberation Study at a
West Coast academic medical center. The study recruited
and prospectively followed patients with metastatic dis-
ease as they exhausted standard therapies. Trained
fieldworkers observed patient-oncologist clinical encoun-
ters, conducted in-depth semi-structured interviews with
patients and their caregivers about treatment and clinical
trial decision-making, and collected structured demo-
graphic data from each patient. All interviews were digi-
t a l ly recorded and pro fes s iona l ly t r ansc r ibed .
Fieldworkers sought follow-up observations and inter-
views with patients after 6 and 12 months. Many patients
had incomplete follow-up due to advancing disease or
death. Informed consent was obtained from all individual
participants included in the study.
As data collection proceeded, we developed a code-
book that reflected theoretically-important concepts and
behaviors from the literature as well as themes and con-
cepts that emerged during data collection. We entered all
observational and interview data into ATLAS.ti qualita-
tive data analysis software (ATLAS.ti version 7.5,
Berlin, Germany). We trained a team of three coders to
code all of the qualitative data in ATLAS.ti and achieved
inter-coder reliability kappa scores above 0.80, which in-
dicates high agreement [38].
In this analysis, we use data from the 13 melanoma patients
in the study. They participated in 1 to 3 clinic observations
(n = 26) and 1 to 3 interviews (n = 29) between Fall 2011 and
Fall 2013. The in-depth semi-structured patient interviews
typically lasted 60–90 min and occurred at a location of the
patient’s preference (e.g., their home, a private office at the
cancer clinic, or the clinic’s infusion center). All interviews
addressed a variety of topics that the literature and investiga-
tors’ preliminary work indicated were relevant to treatment
decision-making, including the participant’s: cancer diagno-
sis, treatment history, and treatment experiences; understand-
ing and evaluation of treatment options; decisions and moti-
vations related to their cancer care; social support;
information-seeking; spirituality; and others’ involvement in
decision-making. Second and third interviews sought to cap-
ture updates on these same topics. As the study was designed
to allow for the naturalistic investigation of patient knowledge
of and decision-making about early-phase trials, field workers
asked about clinical trials only after the participant raised the
topic themselves.
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Analyses
Inductive qualitative analysis
For the inductive qualitative analysis, we reviewed patients’
case summaries and coded data from ATLAS.ti. We focused
on observational data on treatment discussion in clinics and on
the patient’s interview data about treatment decisions,
information-seeking activities, preferences and priorities, and
interactions with providers. We employed a constant compar-
ative approach to iteratively identify and characterize analytic
themes and patient narratives in the data [39, 40].
Heatmap analysis
To investigate patterns of themes within the ethnographic da-
ta, we used an innovative heatmapping procedure—called an
Bethnoarray^—that we developed previously during the
Cancer Patient Deliberation Study [34, 35]. It provides a plat-
form on which to visually analyze patterns both within and
across cases in the sample. Heatmaps have long been de-
ployed as an effective visual tool in the biological and social
sciences. The ethnoarray approach employed here is unique in
that it combines the systematic quantification and color-
coding of multi-level ethnographic data with the use of pri-
marily inductive statistical techniques [35, 41].
An ethnoarray heatmap is a column-by-row grid in which
each individual patient case is represented as a column, and in
which rows represent the qualitative data that has been the-
matically coded in ATLAS.ti. The cells of the grid are shaded
to capture the presence/absence of a particular coded theme in
a given patient’s data. The ethnoarray facilitates identification
of patterns in complex ethnographic data in two ways. First,
analysts can visually inspect the heatmap to examine how
themes or patient experiences cluster together. Second, pat-
terns within the heatmap can be identified using computation-
al techniques found in inductive statistical approaches and
data science. The ethnoarray methodology has been described
in detail elsewhere [34, 35].
We constructed an ethnoarray that included 13 columns
(one for each melanoma patient) and 19 rows (one for each
ATLAS.ti code that captured a theme or subtheme identified
in inductive analysis), totaling 104 cells. Using the R statisti-
cal platform, we applied complete-link hierarchical clustering
in order to group patients based on observed similarities in the
data [35]. We held the ordering of the rows constant so that
related themes remained grouped together. Using this clus-
tered ethnoarray, we examined which qualitative themes were
salient for which patients and noted the extent to which pa-
tients clustered into distinct groups.
Finally, we checked the clustering results against the nar-
rative data and drew on both sources iteratively to characterize
the resultant groups. We used self-reported demographic data
to further describe them.
Results
Sample characteristics
The sample consisted of 13melanoma patients withmetastatic
disease, evenly split with respect to gender (Table 1). All
patients self-identified as White, non-Hispanic; one patient
indicated he was also American Indian. Most patients had less
than a college degree (8 of the 13) and age ranged from 33 to
72 years, with a mean of 59.
Inductive analysis: exploring themes
in decision-making
Our analysis identified eight broad themes that were salient in
patients’ decision-making processes (see Table 2). Some of
these were similar across patients in the sample, such as
conducting personal research about the disease, but most var-
ied considerably. We describe the themes here and present
examples from the data in Table 2.
Involvement in treatment discussions and decisions
Many patients in the sample demonstrated high levels of in-
volvement in discussions and decisions about their treatment.
For example, some regularly evaluated, even scrutinized, their
provider’s recommendations. Other patients interacted collab-
oratively with their provider, contributing substantive infor-
mation and ideas in discussions of treatment options. Other
patients, however, demonstrated non-involvement or very
limited involvement in treatment decisions. Most of these pa-
tients described their decisions about treatment or clinical tri-
als as led by their provider. When they described having a role
in decision-making, it was typically to endorse something
their doctor suggested.
Intensive information seeking
All patients in the sample reported that they or their caregiver
looked up information about their disease or treatments, most-
ly via online research from home. A subset of patients also
made particularly intensive efforts to gather information about
their care options, including consulting with multiple oncolo-
gists, seeking a second opinion about a specific treatment, or
both. These Bhigh burden^ activities provided information
and sometimes gave patients a different perspective on their
disease or treatments.
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Access to medical knowledge
Patients varied substantially regarding their access to medical
or scientific expertise. The information that some patients
brought to clinic discussions reflected their ownmedical back-
ground, e.g., as someone who had provided physical therapy
to oncology patients. Other patients accessed medical infor-
mation from their social network, such as a family member or
former physician-employer. Other patients, however, lacked
medical expertise themselves and in their personal networks,
and primarily relied on their providers for medical information
and counsel.
Interest in clinical trials
Several patients were interested in clinical trials, and many
came to an academic center with experimental therapy in
mind. Many described seeking out or favoring an academic
center because of its reputation as a research facility on Bthe
cutting edge^ of cancer care. Other patients expressed little
interest in trials at the debut of their care. Many of these pa-
tients nevertheless became interested clinical trials in the
course of their treatment.
Optimism
Some patients emphasized a feeling of optimism about an
available treatment option or treatment decision. Some de-
scribed optimism or hopefulness about their general outlook
or their disease trajectory more broadly. Still other patients
indicated they made one or more specific treatment decisions
based on their feeling hopeful about it. This was particularly
true of those who elected to participate in a clinical trial.
Relationship with oncologist
All patients who mentioned their relationship with their on-
cologist indicated they were satisfied with the care their on-
cologist provided. A subset of patients described their oncol-
ogist in particularly positive terms, often related to trust, re-
spect or affection. Some individuals also reported having a
particularly good communication dynamic with their oncolo-
gist, for example citing the doctor’s clear explanations or com-
mitment to discussing all of the patient’s questions.
Decision strategies
We identified four strategies, used alone or in combination,
that patients employed for making individual treatment de-
cisions. Several patients partnered with others, such as
their family caregiver or their oncologist, to make deci-
sions. Some patients used an intuitive strategy, basing their
decisions on what Bfelt right^ and Bfollowing their gut.^
Others used an instrumentally rational strategy, weighing
pros and cons and drawing on facts to decide between
different options. Finally, some patients faced decisions
over which they felt they had no choice because the path
ahead was self-evident or the only one available. In these
situations, the patients often described their role as merely
going along with the Bonly option.^
Decision-making motives
Finally, patients expressed a variety of motivations or
priorities when making a particular decision. These fell
primarily into three categories. Prolonging life manifest-
ed as the wish to extend time until death, to forestall
Table 1 Characteristics of study participants
Age range (years) Gender Education Race and ethnicity Relationship status Annual household income ($)
P1 50–60 M Some college Non-Hispanic White Divorced/separated 60–80k
P2 60–70 M H.S. degree Non-Hispanic White and American Indian Married/partnered 60–80k
P3 40–50 F Some college Non-Hispanic White Married/partnered 40–60k
P4 60–70 F Adv. degree Non-Hispanic White Married/partnered 80–100k
P5 60–70 M Assoc. degree Non-Hispanic White Married/partnered 40–60k
P6 70–80 M Adv. degree Non-Hispanic White Married/partnered 100k+
P7 50–60 M Assoc. degree Non-Hispanic White Married/partnered [missing]
P8 30–40 F H.S. degree Non-Hispanic White Divorced/separated 40–60k
P9 70–80 F Assoc. degree White [ethnicity missing] Divorced/separated 100k+
P10 70–80 F H.S. degree Non-Hispanic White Married/partnered [missing]
P11 50–60 F H.S. degree Non-Hispanic White Married/partnered 40–60k
P12 60–70 M Adv. degree Non-Hispanic White Married/partnered 100k+
P13 40–50 M Some college Non-Hispanic White Married/partnered 60–80k
F female, M male, Adv. advanced, Assoc. associates, H.S. high school
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Table 2 Thematic definitions and examples
Definition Example
1. Involvement in treatment discussions and decisions
High
involvement*
In patient-provider discussions leading up to treatment deci-
sions and in treatment decision-making itself, the patient (P)
performed an evaluating or collaborating role. Evaluating Ps
regularly evaluated, even scrutinized, oncologist (O)
recommendations or decisions; P had own interpretations of
opinions, symptoms, and recommendations. Collaborator Ps
provided regular and substantive (informational or opinion)
input into the patient-provider considerations of treatments
and other medical decisions.
P4 (F, 60s, adv.) readily provided her own analysis of
symptoms and side effects in discussions with her provider.
P3 (F, 40s, some college) says understanding why her O
recommended a treatment is a Bhuge part^ of her wellbeing
BI want to know that what I’mdoing is really the best opinion
for me... Is there something else out there?^
Low involvement In patient-provider discussions leading up to treatment
decisions and in treatment decision-making itself, the P
demonstrated or described a limited role, e.g., no
involvement; approving the provider’s recommendation; or
only occasionally contributing information or opinion.
BIt was always our decision but I would always ask him, you
know, which way does he want to go. ‘Cause I do not see
how you ask a patient which direction you want to go, you
know… It makes no sense… Sowe prettymuch followed his
lead^
(P7, M, 50s, Assoc.).
B[Providers] decided to put me on this trial^ (P10, F, 70s, H.S.).
2. Intensive information-seeking
Multiple consults* P reported actively researching and evaluating different Os for
their care.
BI took a trip to see Dr. [x] at, what is it, is it [institute]...
And I also went to see another melanoma physician, and I’m
drawing a blank now on his name, in [x] institution^
(P6, M, 70s, adv.).
Second opinion* P reported getting a second opinion from another medical
provider about their disease and/or treatments.
BIt wasn’t like I was going to [other medical center] to find the
magic bullet. It was my way of sort of getting away from out
here, getting ...someone else to look at it and step back and
say, ‘Okay, this is what we are going to do’^ (P1, M, 50s,
some college).
3. Access to medical knowledge
Patient* P had substantial experience, formal training, or substantial
informal training in medicine, health or science.
P9 (F, 70s, Assoc.) worked as specialized support staff in an
oncology ward.
P3 (F, 40s, some college) worked for years for an oncologist.
P6 (70s, M, adv.) had formal training in biological sciences and
had been an executive for a pharmaceutical company.
Network* P had substantial access to medical expertise or advice through
a very close contact (e.g., family member) and/or a contact
that was accessed regularly, and/or multiple contacts.
P11’s (F, 50s, H.S.) son-in-law is an aspiringmedical researcher
and her daughter is a nurse. Both frequently provided
information, advice, and research support.
4. Interest in clinical trials
Sought out
trial(s)*
P talked about or described being interested in cancer clinical
trials early in their care (e.g., brought it up to O, researched
available trials). There is evidence that O was not the first to
alert or attract P to clinical trials.
P4 (F, 60s, adv.) came to [cancer center] with the hope of
participating on a phase II clinical trial, and described herself
as Broaring down^ from her out-of-region home to determine
if she was eligible.
Considered
starting trial(s)*
P talked about plans to start, or interest in starting, a specific
clinical trial.
BYeah, [other clinic] is doing a clinical trial that I would be open
to doing... they are getting some good results… [O] is finding
out if there were spots up there for me^ (P8, F, 30s, H.S.).
5. Optimism
Positive outlook* P indicated optimism or positivity in their general outlook
toward cancer, treatment, or illness.
BI am just a very lucky person. I have been so sick. I don’t know
how I have survived^ (P2, M, 60s, H.S.).
BI know how bad my disease is. But I will be perfectly honest.
I feel good. I do not have this sense of like an impending
doom. I just know that it’s going to have a good outcome^
(P3, F, 40s, some college).
Hope in decision* P indicated hope or optimism about a decision. BWe are doing this because we hope it will help...it’s better than
not getting anything^ (P13, M, 40s, some college).
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disease progression, and even to find a cure so as not to
die of advanced cancer. Additionally, some patients
discussed a desire to enhance or maintain the quality of
their lives, and they raised these concerns in the context
of considering specific treatments or trials. Some individ-
uals even rejected a given treatment option because they
believed it would diminish their quality of life. Finally, a
number of patients indicated that altruism—a desire to
help others—influenced their decision-making. These
considerations arose specifically when they were consid-
ering a trial offer or discussing hypothetical trial
participation.
Table 2 (continued)
Definition Example
6. Relationship with oncologist
Very positive* P explicitly described liking, respecting and/or trusting their O. BI think he is a very good doctor. I think he really cares about
me…And he’s got a good sense of humor, which is nice, and
I like him, I respect him^ (P8, F, 30s, H.S.).
Good
communication*
P described O as communicating well with them, having good
communication skills in general, or P and O understanding
each other.
From observational fieldnotes: P6 (M, 70s, adv.) Bfelt that [O]
was always open to questions and that he felt there was
always plenty of time to ask and receive answers to whatever
he wanted.^
7. Decision strategies
Partner with
doctor*
P reported or demonstrated that they made a decision in
partnership with their physician.
BDr. [x] always offered opinions and then we would decide
together which way we would go^ (P7, M, 50s, Assoc.).
Partner with
family*
P reported or demonstrated that they made a decision in
partnership with one or more family members.
BWe make all decisions together and in consultation with our
son, who’s a doctor also^ (P12, M, 60s, adv.).
Intuitive* P described or demonstrated using an emotional or intuitive
style, e.g., Bfeeling^ or Bjust knowing^ something is the right
thing to do, or Bknowing^ the right course of action.
In choosing [cancer center]: BI do do [research] on the Internet
but I did make some phone calls and you know, just, I don’t
know.
I just felt like this was where I needed to go^ (P3, F, 40s,
some college).
Rational* P described or demonstrated using an instrumentally rational
style, e.g., weighing pros and cons, drawing on facts to
decide.
BI looked at [this drug] really hard and I decided that it was not a
drug that I would ever want to try. I do not like the
autoimmune side effects that it has and the successes that
they are having are just not worth, it’s just not worth it^
(P8, F, 30s, H.S.).
Had no choice* P described or demonstrated not having any choices for a given
decision.
On whether Bscary^ risks of a clinical trial changed P’s thinking
about whether or not he would do it: BNo... Well, because I
do not have any other alternative^ (P10, F, 70s, H.S.).
8. Motives
Longer
life/survival*
P indicated staying alive, prolonging life, or getting rid of
cancer was a key motive in decision-making.
This [‘scary’ treatment] is just what you do because you want to
live (P8, F, 30s, H.S.).
BI definitely want to live for another year or 2...^
(P2, M, 60s, H.S.).
Quality of life* P indicated improving or maintaining quality of life was a key
motive in treatment/trial decision-making.
On deciding against brain radiation: BIt makes you have no
memory... it kind of crispy critters your brain….I like to
knowwho I am and who everybody around me is, and if I do
not have that, what are you saving?^ (P2, M, 60s, H.S.).
Altruism* P indicated helping improve society or the lives of others as a
key motive in decision-making.
BJust wanting to know that someday what I did made a
difference...whether it’s my children or grandchildren or
some girl in Haiti that I do not even know.... that instantly
they would know that there was something that could be
done and they do not have to become a statistic... That was
definitely part of my thinking when I was considering a
clinical trial...^ (P3, F, 40s, some college).
P patient, O oncologist(s) involved in P’s care, F female, M male, Adv. advanced degree, Assoc. associate’s degree, H.S. high school degree
*These themes appear as rows in the ethnoarray (Fig. 1)
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Ethnoarray analysis: identifying patterns
among themes
For each patient, the ethnoarray depicts the presence or ab-
sence of themes and subthemes identified above (Table 2), and
it highlights how these varied across patients. Hierarchical
clustering sorted patients (columns) into two major groupings,
as indicated by the dendogram Bbrackets^ across the top of the
graphic (Fig. 1). These groups differ substantially in several
regards.
For patients in group A, there is little indication of high
involvement in decision-making, high-burden actions to in-
form decisions, access to insider medical/scientific knowl-
edge, or early trials seeking. A higher proportion of group A
patients expressed altruistic motivations and cooperated with
doctors on decisions than did group B members.
Nearly all patients in group B demonstrated high involve-
ment in decision-making discussions, participated in high-
burden information-seeking activities, had access to medical
or scientific expertise through themselves or a network contact,
and sought out trials early in their care. A higher proportion of
group B patients reported good communication with their pro-
viders, made decisions based on hope or hopefulness, and used
an instrumentally rational decision-making style (e.g., relying
on facts, weighing pros and cons) than did group A.
The groups were similar in terms of patient relationship with
the provider and their interest in or plans for starting a clinical
trial. Patterns for other factors were too subtle to interpret.
Characterizing decision-making types
Drawing on both the narrative data and the ethnoarray cluster-
ing, we identify two broad approaches to treatment decision-
making, which we label Breliant outsiders^ and Bactive
insiders.^ Case examples of these types are presented in Table 3.
Reliant outsiders viewed their role in treatment
decision-making as relatively limited. They saw their pro-
viders as an appropriate and desirable source of guidance
and leadership on most medical decisions. For most, their
provider was their only source of medical information ger-
mane to their care. Despite having sought care at a research
institution, this group entered their therapeutic relationship
with little or no demonstrated interest in clinical trials.
However, nearly all later considered experimental involve-
ment. When they felt they had a decision to make, they did
so in partnership with family or a provider. Many consid-
ered the possibility of helping others (e.g., future patients)
when making their decisions.
Active insiders (group B) were more engaged in discus-
sions around treatment decisions. Nearly all demonstrated ear-
ly and enthusiastic interest in clinical trials, had access to
considerablemedical or scientific expertise outside the clinical
setting, and participated in intensive information-seeking
activities. These patients were diverse in their decision strate-
gies. Nearly all indicated that intuition or hope had played a
part in their decisions, but many also drew on facts and con-
sidered the pros and cons of their options.
Demographically, the groups are similar in terms of age
ranges and mean age (62 vs. 58), and there is virtually no
variation in race or ethnicity in the sample. The proportion
of women, however, is considerably higher among active in-
siders (5 of 8) than among reliant outsiders (1 of 5, see
Table 4). Additionally, none of the reliant outsiders had a
college degree, while nearly half (3/8) of active insiders had
a master’s degree or higher.
Discussion and conclusion
Discussion
This ethnographic investigation identified several factors that
characterize how patients with late-stagemelanoma approached
their treatment decision-making. Using an innovative analytic
approach, we discovered that these factors clustered into two
groups, which we characterized as reliant outsider and active
insider approaches to decision-making. These differ particularly
in terms of patient-provider dynamics, patient access to
Binsider^medical information, and the degree to which patients
assumed an active role inside medical institutions. We observed
patterns relating certain demographic characteristics to the
groups (gender, educational attainment), but membership was
not determined solely by these factors. These analyses highlight
the complex ways social, behavioral, and individual factors
shape treatment decision-making.
These findings add to the literature on decision-making by
providing in-depth information on how some late-stage mel-
anoma patients are approaching their decisions amid increas-
ingly complex treatment regimens. In addition to systemic
chemotherapy, palliative radiation, and palliative surgery, pa-
tients with advanced melanoma may now use immunother-
apies, targeted therapies, or combinations of them, either in
standard usage or in the clinical trial pipeline. Research on
melanoma patients’ perspectives is particularly timely as the
annual incidence rates for melanoma in the USA have in-
creased significantly and may affect as many as 112,000
new patients per year by 2030 [42, 43]. These trends suggest
an increased need to understand howmelanoma patients make
decisions and how these decision-making approaches may
relate to patient care and outcomes.
The study may also contribute to the understanding of can-
cer patients’ decision-making more broadly. Most analyses on
this topic have focused on one or a narrow set of patient
considerations, interactional styles, or specific decisions.
Such studies provide partial glimpses into a dynamic and
complex process. To understand cancer patients as decision-
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makers in real-world settings, with their disparate resources
and social contexts, a holistic and person-centered analysis is
required [14, 33]. This study joins a small field of such studies
[14, 15, 24, 25, 44] and contributes to it an innovative analytic
approach that facilitates the rigorous and transparent analysis
of complex qualitative data. Ethnoarray analysis enabled us
both to consider how diverse factors shaped individual pa-
tients as decision-makers and to identify differences in how
groups of patients approached decision-making as a whole.
This approach can be applied to decision-making in other
late- or early-stage cancer patient populations.
Finally, enhanced understanding of patients as decision-
makers, and the factors that shape their decision-making
process, is necessary to develop effective supports for
shared decision-making and patient-centered care [11,
33]. Existing scholarship has documented associations be-
tween patient demographic characteristics, preferences,
and decision-making behaviors [11–13, 16, 45].
Ethnographic patient-centered research, however, can illu-
minate the context and nuance of these associations. For
example, our findings reveal different approaches to
decision-making even within a racially homogenous
group, and they reveal how these differences are enacted.
Additionally, we find that among patients with lower levels
of education in our sample, substantial access to medical or
scientific expertise differentiates between those with high
and low levels of involvement in treatment decisions. All
of the active insiders with less than a college degree had
access to such Binsider^ knowledge via their own back-
ground (2 of 5) or their immediate social network (4 of
Fig. 1 Clustered ethnoarray of factors in advanced melanoma patients’ treatment decision-making (n = 13)
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5), whereas only one of the five reliant outsider patients
had such a resource. This suggests that enhancing vulner-
able patients’ access to individuals with medical expertise
(e.g., via health navigators, lay health educators, and other
health literacy mediators [46–49]) may be a promising in-
tervention target for supporting their involvement in treat-
ment decision-making. Additional research is needed to
confirm this. Overall, we posit that greater awareness of
such stylistic differences, and of their diversity within even
demographically-similar populations, may help providers
to more effectively evaluate and tailor their communication
efforts with their patients.
Limitations
The study has several limitations, mostly reflecting the
limited number of late-stage melanoma patients who par-
ticipated, single-site recruitment from an academic medical
center, and limited diversity within the sample. The inclu-
sion of other sites and other racial and ethnic groups would
have strengthened the analysis. More research is needed to
assess the generalizability of our findings to other popula-
tions of melanoma and late-stage cancer patients. The clus-
tered ethnoarray also has limitations. Analyses of larger
samples may identify more and more nuanced approaches
Table 3 Exemplar case descriptions from group A (reliant outsider) and group B (active insider)
Reliant outsider Active insider
Dennis (P7) is a white carpenter in his 50s who was referred to the cancer
center after a lengthy diagnosis process. After learning he had
melanoma, Bthere was only one option. It was go to [cancer center] and
start treatment with [oncologist].^ He tells the interviewer that he does
not know much about the different treatments available to him: Bit’s all
mumbo jumbo to me… I am not big into reading up on stuff like that.^
His caregiver wife, a cashier, keeps track of this information. In the
course of this experience Dennis did not look for second opinions. He
described his decision-making process as: Balways our decision, but I
would always ask [oncologist], you know, which way does he want to
go. ‘Cause I do not see how you ask a patient which direction you want
to go, you know, when a doctor’s been doing this for however many
years. It makes no sense. So we pretty much just kind of let him -- I
mean, we agreed to everything that he wanted to do so we let, you know,
pretty much followed his lead.^ He could not remember any point when
he and his wife second-guessed a decision made that way. After a year of
care at [cancer center] he was told there were no remaining anti-cancer
options for him unless he was willing to travel outside of California for
trials, something he was not willing to do.
Gary (P12) is a white semi-retired engineer in his 60s. When he was
diagnosed he and his wife did not know anyone with melanoma, so they
relied on research they did, their MD son’s insights, and information and
referrals they secured from doctors at three different institutions. Gary
and his wife were proactive and effective in pushing for the care they
wanted with the providers they wanted. Gary described his approach to
decision-making as relatively Bcautious^: BWe make sure we got the
whole picture before we make a decision.^ He described weighing the
pros and cons of different courses of action. Gary, his caregiver wife and
MD son used information they found via research and medical
networking tomake decisions together as a Bteam.^ Throughout his care,
Gary scrutinized oncologists’ descriptions of the risks of different
treatments, as his MD son had told him that oncologists tended to
minimize the severity of treatment side effects. From early on Gary saw
PD1 trials as the only potentially efficacious option available to him:
BThey have given me the distinct impression that this is a much better,
although still experimental drug, both for minimizing side effects and
chances of success… I want to get into [it] very badly and… as soon as
possible…We have never wavered from that approach.^
Table 4 Characteristics of study participants and decision approach type
Age range
(years)
Gender Education Race and ethnicity Relationship
status
Annual household
income ($)
Decision
approach type
P1 50–60 M Some college Non-Hispanic White Divorced/separated 60–80k Active insider
P2 60–70 M H.S. degree Non-Hispanic White and American Indian Married/partnered 60–80k Reliant outsider
P3 40–50 F Some college Non-Hispanic White Married/partnered 40–60k Active insider
P4 60–70 F Adv. degree Non-Hispanic White Married/partnered 80–100k Active insider
P5 60–70 M Assoc. degree Non-Hispanic White Married/partnered 40–60k Reliant outsider
P6 70–80 M Adv. degree Non-Hispanic White Married/partnered 100k+ Active insider
P7 50–60 M Assoc. degree Non-Hispanic White Married/partnered [missing] Reliant outsider
P8 30–40 F H.S. degree Non-Hispanic White Divorced/separated 40–60k Active insider
P9 70–80 F Assoc. degree White [ethnicity missing] Divorced/separated 100k+ Active insider
P10 70–80 F H.S. degree Non-Hispanic White Married/partnered [missing] Reliant outsider
P11 50–60 F H.S. degree Non-Hispanic White Married/partnered 40–60k Active insider
P12 60–70 M Adv. degree Non-Hispanic White Married/partnered 100k+ Active insider
P13 40–50 M Some college Non-Hispanic White Married/partnered 60–80k Reliant outsider
F female, M male, Adv. advanced, Assoc. associates, H.S. high school
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than could be identified here. Additionally, clustering re-
sults cannot be used uncritically; they must be interpreted
and checked in conversation with the associated narrative
data. Finally, as with all classificatory analyses, the char-
acteristics of the resulting groups may not perfectly de-
scribe the characteristics of each of its members.
Responsible and transparent interpretation of clustered
ethnoarrays must acknowledge these complexities.
Conclusion
These findings contribute a nuanced and holistic perspective
on treatment decision-making among late-stagemelanoma pa-
tients that advances scholarly understanding of the process.
These findings may provide helpful targets for interventions
designed to support cancer patients as decision-makers.
Moreover, this work illustrates the potential utility of
ethnoarray analysis for pursuing rigorous person-centered
analysis of medical decisions. Future research must investi-
gate the applicability of these findings to other settings and
discover if the identified decision-making approaches are tied
to important patient outcomes.
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